LABU’s bearish cousin is the Direxion Daily S&P Biotech Bear Shares (NYSEArca: LABD). The two are the first triple-leveraged biotech ETFs to come to market.
From 2012 through 2014, an average of three biotech ETFs were found among each year’s 10 best sector ETFs. This year, that number has swelled to six, which is to say there have certainly been times when a leveraged bullish biotech ETF was a fine idea.
Direxion has had success with leveraged healthcare ETFs, namely the Direxion Daily Healthcare Bull 3x Shares (NYSEArca: CURE). CURE is one of the fastest-growing leveraged ETFs and was recently split 4-for-1, giving it a more approachable price tag of just over $40 at Monday’s close.
Tables Courtesy: Direxion